Abstract P251 Figure 1 Consistency between doctors when reporting CXRs in the context of possible CAP (k with 95% CI).

Conclusions In the context of possible pneumonia, the CXR was not consistently reported by any group. Junior doctors were more consistent than attending consultants and radiologists were most consistent. A possible explanation for these differences is that junior doctors, by necessity, have developed similar ideas of what they will consider pneumonia where as consultants who less frequently make the initial diagnostic decision vary in their criteria for diagnosing pneumonia. This study does not present a “gold standard” interpretation and therefore does not address the issue of accuracy but it does raise questions about to what extent the CXR ever be regarded as a “reliable” diagnostic test.

COPD and drugs: new and old concepts

P252 ONCE-DAILY NVA237 IMPROVES SYMPTOMS, AND REDUCES COPD EXACERBATIONS AND ASSOCIATED HOSPITALISATIONS: THE GLOW1 TRIAL

1D’Uzzo, 2J A van Noord, 3C Martin, 4R Horton, 5D Banerji, 6Y Lu, 7V K T Alagappan, 8T Overend. 1Department of Family and Community Medicine, University of Toronto, Ontario, Canada; 2Attilio Medisch Centrum, Heerlen, The Netherlands; 3Novartis Horsham Research Centre, Horsham, West Sussex, UK; 4Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Introduction Symptoms profoundly impact daily life of COPD patients. We assessed the influence of the once-daily (qd) long-acting muscarinic antagonist (LAMA) NVA237 (glycopyrronium bromide) on symptoms and exacerbations in patients with moderate-to-severe COPD.

Methods Patients were randomised (2:1) to 26 weeks double-blind treatment with NVA237 50 μg qd or placebo (PBO). Study drugs were administered via a single-dose dry powder inhaler (Breezhaler® device). Primary efficacy endpoint: trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose values) vs PBO after 12 weeks.

Results 322 patients were randomised; mean age was 63.9 years, mean post-bronchodilator FEV1 was 55% predicted. 80.5% completed the study. At Week 12 there was a statistically significant and clinically relevant difference between NVA237 vs PBO in mean trough FEV1 (108 ml; p<0.001). Trough FEV1 was also significantly higher at Day 1 and Week 26 (treatment difference: 105 ml and 113 ml, respectively; p<0.001). Serial spirometry in a subpopulation of patients showed statistically superior (p<0.001) and clinically meaningful improvements in FEV1 vs NVA237 at PBO at all timepoints on Day 1, Week 12 and Week 26. NVA237 had a rapid onset of action with an increased FEV1 of 93 ml at 5 min and 144 ml at 15 min vs PBO after the first dose on Day 1 (p<0.001). Overall, the incidence of adverse events (AEs) was similar between treatment groups (NVA237: 57.5%; PBO: 65.2%). Serious AEs were reported by 7.5% of NVA237- vs 9.0% of PBO-treated patients.

Conclusion NVA237 50 μg once daily was generally safe and well tolerated. Improvements in bronchodilation were rapid, clinically meaningful and maintained for 24 h throughout the study.

P253 NVA237 ONCE DAILY OFFERS RAPID AND CLINICALLY MEANINGFUL BRONCHODILATION IN COPD PATIENTS THAT IS MAINTAINED FOR 24 H: THE GLOW1 TRIAL

111 D’Uzzo, 2G Ferguson, 3C Martin, 4V K T Alagappan, 5D Banerji, 6Y Lu, 7R Horton, 8T Overend. 1Department of Family and Community Medicine, University of Toronto, Ontario, Canada; 2Pulmonary Research Institute of Southeast Michigan, Livonia, Michigan, USA; 3Novartis Horsham Research Centre, Horsham, West Sussex, UK; 4Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Introduction NVA237 (glycopyrronium bromide) is an inhaled long-acting muscarinic antagonist (LAMA) in development for the once-daily (qd) treatment of COPD. The GLOW1 study evaluated the efficacy and safety of NVA237 in patients with moderate-to-severe COPD.

Methods Patients were randomised (2:1) to 26 weeks double-blind treatment with NVA237 50 μg qd or placebo (PBO). Study drugs were administered via a single-dose dry powder inhaler (Breezhaler® device). Efﬁcacy endpoint: trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose values) vs PBO after 12 weeks.

Results 322 patients were randomised; mean age was 63.9 years, mean post-bronchodilator FEV1 was 55% predicted. 80.5% completed the study. At Week 12 there was a statistically significant and clinically relevant difference between NVA237 vs PBO in mean trough FEV1 (108 ml; p<0.001). Trough FEV1 was also significantly higher at Day 1 and Week 26 (treatment difference: 105 ml and 113 ml, respectively; p<0.001). Serial spirometry in a subpopulation of patients showed statistically superior (p<0.001) and clinically meaningful improvements in FEV1 vs NVA237 at PBO at all timepoints on Day 1, Week 12 and Week 26. NVA237 had a rapid onset of action with an increased FEV1 of 93 ml at 5 min and 144 ml at 15 min vs PBO after the first dose on Day 1 (p<0.001). Overall, the incidence of adverse events (AEs) was similar between treatment groups (NVA237: 57.5%; PBO: 65.2%). Serious AEs were reported by 7.5% of NVA237- vs 9.0% of PBO-treated patients.

Conclusion NVA237 50 μg once daily was generally safe and well tolerated. Improvements in bronchodilation were rapid, clinically meaningful and maintained for 24 h throughout the study.

P254 NVA237 ONCE DAILY IMPROVES EXERCISE ENDURANCE IN PATIENTS WITH COPD FROM THE FIRST DOSE: THE GLOW3 TRIAL

1D Singh, 2K Beeh, 3A Drullmann, 4L Di Scala, 5R Smith. 1University of Manchester, Medicines Evaluation Unit, Manchester, UK; 2Astrid Respiratory Research Institute, Wiesbaden, Germany; 3Novartis Pharma AG, Basel, Switzerland; 4Novartis Horsham Research Centre, West Sussex, UK

Introduction The fundamental characteristics of COPD are exertional dyspnoea and exercise limitation, which are associated with